The Lynx Group

Dual FLT3 and CDK4/6 Inhibition Shows Modest Activity in Relapsed/Refractory AML

Conference Correspondent

A common resistance mechanism in internal tandem duplication (ITD)-mutated FLT3 acute myeloid leukemia (AML) is the acquisition of kinase domain or gatekeeper mutations in the FLT3 gene. FLX925 is a next-generation FLT3 inhibitor developed to overcome the resistance mechanisms and to inhibit CDK4/6. The results of a phase 1 dose-escalation study of FLX925 in adult patients with relapsed or refractory AML were presented at ASH 2017.

Patients aged ≥18 years with adequate performance status (Eastern Cooperative Oncology Group ≤2) and organ function, and relapsed or treatment-refractory AML were enrolled, regardless of FLT3 mutation status.

A total of 51 eligible patients received FLX925 oral monotherapy at doses ranging from 40 mg twice daily to 720 mg 3 times daily. The median age of the study population (n = 51) at screening was 60 years (range, 19-81 years) and the majority were white (76.5%); 20 patients had FLT3-ITD–positive AML, 8 patients had FLT3-D835–mutant AML, and 5 patients carried dual mutant disease. Patients received a median of one 4-week cycle of treatment (range, <1-6 cycles).

At the FLX925 720-mg 3-times-daily dose, 1 dose-limiting toxicity (DLT) of elevated creatinine was noted; a second report of acute renal failure not meeting strict DLT criteria was also reported. The maximum tolerated dose of FLX925 was determined to be 540 mg 3 times daily. Patients in the 3 highest-dose cohorts (≥540 mg twice daily) experienced treatment-related adverse events (TRAEs). The most common TRAEs (any grade) included nausea (7.8%), diarrhea (5.9%), increased creatinine (9.8%), acute or chronic renal failure (7.8%), and decreased white blood cell count (5.9%). Of these, treatment-related serious adverse events included 1 report of increased transaminase (2%), 2 reports of increased creatinine (3.9%), and 4 reports of acute renal failure.

Pharmacokinetic studies demonstrated mean Tmax values ranging from 1.30 to 4.38 hours after the first dose, and mean T1/2 values ranging from 2.31 to 7.72 hours during cycle 1.

In terms of efficacy, there was no evidence of clinical activity in the first 5 cohorts involving 30 subjects (40-360 mg orally twice daily). In the ≥540-mg twice-daily cohorts (n = 21), 8 showed antileukemic activity, including ≥50% reductions of peripheral blasts in 6 patients (3 ITD or ITD/D835, 2 D835, and 1 FLT3 wild-type), and 2 patients who achieved a transient morphologic leukemia-free state (<5% bone marrow blasts without count recovery; 1 ITD or ITD/D835, 1 D835). No complete or partial responses were reported.

The researchers concluded that single-agent FLX925 showed modest evidence of antileukemic activity, which was hypothesized to be due to dose-limiting adverse events that precluded prolonged dosing at higher dose levels.

Daver N, et al. 2017 ASH. Abstract 1343.

Related Articles


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: